Literature DB >> 22357174

Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients.

Hani M Wadei1, Ziad S Zaky, Andrew P Keaveny, Barry Rosser, Melanie Jones, Martin L Mai, Ilynn Bulatao, Thomas A Gonwa.   

Abstract

BACKGROUND: The role of sirolimus (SRL) conversion in the preservation of kidney function in liver transplant (LT) recipients with calcineurin inhibitor (CNI) nephrotoxicity is unclear.
METHODS: Data on 102 LT recipients with deteriorating kidney function after CNI exposure who were later converted to SRL were retrospectively reviewed. Kidney function was assessed using serum creatinine and estimated glomerular filtration rate (eGFR) at time of conversion and serially thereafter. The primary endpoint was stabilization or improvement of kidney function as assessed by eGFR at last recorded follow-up compared with eGFR at the time of conversion. RESULT: After a median (interquartile range) of 3.1 (1.6-4.5) years of follow-up, serum creatinine decreased from 1.9 ± 0.8 to 1.8 ± 0.7 mg/dL (P=0.25) and eGFR increased from 40.8 ± 16.7 to 44.3 ± 20.0 mL/min (P=0.03). During the same time period, 24-hr urinary protein excretion increased from median (interquartile range) of 72 (0-155) to 382 (169-999) mg/day (P=0.0001). Sixty-five (64%) patients achieved the primary endpoint and 37 (36%) experienced deterioration in kidney function. Independent predictors of deterioration of kidney function after SRL conversion were development of proteinuria ≥ 1000 mg/day (odds ratio [OR]: 3.3, confidence interval [CI]: 1.1-9.5 P=0.03), post-LT diabetes (OR: 4.2, CI: 1.6-11.1, P=0.004), and higher eGFR at time of conversion (OR: 1.6, CI: 1.2-2.2, P=0.003).
CONCLUSION: Improvement or stabilization of kidney function occurred in the majority of LT recipients converted to SRL for CNI nephrotoxicity. Proteinuria ≥ 1000 mg/day, post-LT diabetes, and higher baseline eGFR were independent predictors of kidney function loss after SRL conversion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22357174     DOI: 10.1097/TP.0b013e31824bbd01

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Conversion from calcineurin inhibitors to mTOR inhibitors stabilizes diabetic and hypertensive nephropathy after liver transplant.

Authors:  José M Álamo; Claudia Olivares; Lydia Barrera; Luis M Marín; Gonzalo Suarez; Carmen Bernal; Juan Serrano; Jordi Muntané; Francisco J Padillo; Miguel A Gómez
Journal:  World J Transplant       Date:  2015-03-24

2.  Evaluation and Management of CKD in the Nonkidney Solid Organ Transplant Recipient.

Authors:  Karen M Warburton; Alden M Doyle
Journal:  Clin J Am Soc Nephrol       Date:  2018-01-11       Impact factor: 8.237

Review 3.  Review on immunosuppression in liver transplantation.

Authors:  Maryam Moini; Michael L Schilsky; Eric M Tichy
Journal:  World J Hepatol       Date:  2015-06-08

4.  Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis.

Authors:  Liying Peng; Chanyuan Wu; Ruping Hong; Yiduo Sun; Junyan Qian; Jiuliang Zhao; Qian Wang; Xinping Tian; Yanhong Wang; Mengtao Li; Xiaofeng Zeng
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-09-14       Impact factor: 5.346

Review 5.  The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence.

Authors:  Goran B Klintmalm; Björn Nashan
Journal:  J Transplant       Date:  2014-02-25

6.  Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients.

Authors:  Lung-Chih Li; Chien-Ning Hsu; Chih-Che Lin; Yu-Fan Cheng; Tsung-Hui Hu; Ding-Wei Chen; Chih-Hsiung Lee; Toshiaki Nakano; Chao-Long Chen
Journal:  BMC Gastroenterol       Date:  2017-04-20       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.